SHUKRA PHARMACEUTICALS L
Latest filings
- Promoter warrant conversion: 17.35 lakh shares allotted · Fund Raising
- Company says no undisclosed info behind recent price movement · Regulatory & Legal
- BSE seeks clarification on significant price movement · Regulatory & Legal
Snapshot
What the business is, and whether it's a good one at a fair price.
A Pharmaceuticals & Biotechnology company listed on NSE and BSE.
Scorecard
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
Strengths
Concerns
Charts
How has the market priced it — with filings on the timeline?
SHUKRAPHAR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Peers
How does it stack up on valuation, returns and growth?
Loading peers…
Financials
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Ownership
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Common questions
Answered from SHUKRA PHARMACEUTICALS L's filed financials and exchange disclosures
What does SHUKRA PHARMACEUTICALS L do?
SHUKRA PHARMACEUTICALS L is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol SHUKRAPHAR.
Does SHUKRA PHARMACEUTICALS L pay a dividend?
Yes. The dividend yield is 0.01% at the current price. It paid out 2% of its profit as dividend in FY26.
Is SHUKRA PHARMACEUTICALS L debt-free?
On a net basis, yes. It reported borrowings of ₹5.02 Cr on its 31 Mar 2026 balance sheet, but holds ₹0.96 Cr more cash than debt.
Where can I track SHUKRA PHARMACEUTICALS L's announcements?
Every NSE and BSE filing by SHUKRA PHARMACEUTICALS L appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.